Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia-Reference-Cited by-同舟云学术

Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia

Published:2022-12-16 Issue:4 Volume:110 Page:354-361
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Inzoli Elena¹²^ORCID,Crisà Elena³^ORCID,Pugliese Novella⁴^ORCID,Civettini Ivan¹²^ORCID,Lanzarone Giuseppe⁵^ORCID,Castelli Andrea⁶,Martinelli Vincenzo⁴,Montelisciani Laura⁷^ORCID,Antolini Laura⁷^ORCID,Gambacorti‐Passerini Carlo¹²^ORCID,Elli Elena Maria²^ORCID

Affiliation:

1. Department of Medicine and Surgery University of Milano Bicocca Milan Italy

2. Hematology Division and Bone Marrow Unit, ASST Monza San Gerardo Hospital Monza Italy

3. Division of Hematology, Department of Translational Medicine Università del Piemonte Orientale and Azienda Ospedaliero‐Universitaria Maggiore della Carità Novara Italy

4. Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy

5. SC Hematology Unit AOU Città della Salute e della Scienza di Torino Torino Italy

6. Division of Hematology Ospedale degli Infermi Biella Italy

7. Bicocca Center of Bioinformatics, Biostatistics and Bioimaging (B4 Center) University of Milano‐Bicocca Monza Italy

Funder

Sandoz

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13910

Reference29 articles.

1. Myelofibrosis: an update on current pharmacotherapy and future directions

2. Myeloproliferative disorders

3. Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management

4. Struggling with myelofibrosis-associated anemia

5. Alleviating anemia and thrombocytopenia in myelofibrosis patients